These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 29389803)

  • 21. The substance P/NK-1 receptor system: NK-1 receptor antagonists as anti-cancer drugs.
    Munoz M; Covenas R; Esteban F; Redondo M
    J Biosci; 2015 Jun; 40(2):441-63. PubMed ID: 25963269
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Human positron emission tomography studies of brain neurokinin 1 receptor occupancy by aprepitant.
    Bergström M; Hargreaves RJ; Burns HD; Goldberg MR; Sciberras D; Reines SA; Petty KJ; Ogren M; Antoni G; Långström B; Eskola O; Scheinin M; Solin O; Majumdar AK; Constanzer ML; Battisti WP; Bradstreet TE; Gargano C; Hietala J
    Biol Psychiatry; 2004 May; 55(10):1007-12. PubMed ID: 15121485
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The NK-1 receptor is expressed in human leukemia and is involved in the antitumor action of aprepitant and other NK-1 receptor antagonists on acute lymphoblastic leukemia cell lines.
    Muñoz M; González-Ortega A; Coveñas R
    Invest New Drugs; 2012 Apr; 30(2):529-40. PubMed ID: 21120581
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Opioid-like effects of the neurokinin 1 antagonist aprepitant in patients maintained on and briefly withdrawn from methadone.
    Jones JD; Speer T; Comer SD; Ross S; Rotrosen J; Reid MS
    Am J Drug Alcohol Abuse; 2013 Mar; 39(2):86-91. PubMed ID: 23421568
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Neurokinin-1 receptor is highly expressed in cervical cancer and its antagonist induces cervical cancer cell apoptosis.
    Guan L; Yuan S; Ma J; Liu H; Huang L; Zhang F
    Eur J Histochem; 2023 Jan; 67(1):. PubMed ID: 36629320
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Tranexamic acid induces kaolin intake stimulating a pathway involving tachykinin neurokinin 1 receptors in rats.
    Kakiuchi H; Kawarai-Shimamura A; Kuwagata M; Orito K
    Eur J Pharmacol; 2014 Jan; 723():1-6. PubMed ID: 24333477
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Potential therapeutic effect of NK1R antagonist in diabetic non-healing wound and depression.
    Li M; Ma H; Zhang S; Peng Y; Ding L; Zhang Y; Min P
    Front Endocrinol (Lausanne); 2022; 13():1077514. PubMed ID: 36686487
    [TBL] [Abstract][Full Text] [Related]  

  • 28. NK1R antagonist decreases inflammation and metastasis of breast carcinoma cells metastasized to liver but not to brain; phenotype-dependent therapeutic and toxic consequences.
    Nizam E; Köksoy S; Erin N
    Cancer Immunol Immunother; 2020 Aug; 69(8):1639-1650. PubMed ID: 32322911
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Role of Substance P and Its Receptor Neurokinin 1 in Chronic Prurigo: A Randomized, Proof-of-Concept, Controlled Trial with Topical Aprepitant.
    Ohanyan T; Schoepke N; Eirefelt S; Hoey G; Koopmann W; Hawro T; Maurer M; Metz M
    Acta Derm Venereol; 2018 Jan; 98(1):26-31. PubMed ID: 28853492
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Targeting the Neurokinin-1 Receptor Compromises Canonical Wnt Signaling in Hepatoblastoma.
    Ilmer M; Garnier A; Vykoukal J; Alt E; von Schweinitz D; Kappler R; Berger M
    Mol Cancer Ther; 2015 Dec; 14(12):2712-21. PubMed ID: 26516161
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The Repurposing of Non-Peptide Neurokinin-1 Receptor Antagonists as Antitumor Drugs: An Urgent Challenge for Aprepitant.
    Coveñas R; Rodríguez FD; Robinson P; Muñoz M
    Int J Mol Sci; 2023 Nov; 24(21):. PubMed ID: 37958914
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The in vitro anti-cancer synergy of neurokinin-1 receptor antagonist, aprepitant, and 5-aminolevulinic acid in glioblastoma.
    Ebrahimi S; Mirzavi F; Hashemy SI; Khaleghi Ghadiri M; Stummer W; Gorji A
    Biofactors; 2023; 49(4):900-911. PubMed ID: 37092793
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The Potential In Vitro Inhibitory Effects of Neurokinin-1 Receptor (NK-1R) Antagonist, Aprepitant, in Osteosarcoma Cell Migration and Metastasis.
    Alsaeed MA; Ebrahimi S; Alalikhan A; Hashemi SF; Hashemy SI
    Biomed Res Int; 2022; 2022():8082608. PubMed ID: 36177059
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A randomized controlled study evaluating the efficacy of aprepitant for highly/moderately emetogenic chemotherapies in hematological malignancies.
    Nasu R; Nannya Y; Kurokawa M
    Int J Hematol; 2015 Apr; 101(4):376-85. PubMed ID: 25644148
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Crystal structures of the human neurokinin 1 receptor in complex with clinically used antagonists.
    Schöppe J; Ehrenmann J; Klenk C; Rucktooa P; Schütz M; Doré AS; Plückthun A
    Nat Commun; 2019 Jan; 10(1):17. PubMed ID: 30604743
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Neurokinin 1 receptor antagonists exhibit peripheral effects in prurigo nodularis including reduced ERK1/2 activation.
    Agelopoulos K; Rülander F; Dangelmaier J; Lotts T; Osada N; Metze D; Luger TA; Loser K; Ständer S
    J Eur Acad Dermatol Venereol; 2019 Dec; 33(12):2371-2379. PubMed ID: 31442331
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antiproliferative effects of [D-Pro2, D-Trp7,9]-Substance P and aprepitant on several cancer cell lines and their selectivity in comparison to normal cells.
    Matalińska J; Świć A; Lipiński P; Misicka A
    Folia Neuropathol; 2020; 58(3):237-244. PubMed ID: 33099293
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Modeling and simulation approach to support dosing and study design requirements for treating HIV-related neuropsychiatric disease with the NK1-R antagonist aprepitant.
    Barrett JS; Bajaj G; McGuire J; Wu D; Spitsin S; Moorthy G; Zhao X; Tebas P; Evans DL; Douglas SD
    Curr HIV Res; 2014; 12(2):121-31. PubMed ID: 24862330
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The NK-1 receptor antagonist aprepitant as a broad spectrum antitumor drug.
    Muñoz M; Rosso M
    Invest New Drugs; 2010 Apr; 28(2):187-93. PubMed ID: 19148578
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Targeting tachykinin receptors in neuroblastoma.
    Henssen AG; Odersky A; Szymansky A; Seiler M; Althoff K; Beckers A; Speleman F; Schäfers S; De Preter K; Astrahanseff K; Struck J; Schramm A; Eggert A; Bergmann A; Schulte JH
    Oncotarget; 2017 Jan; 8(1):430-443. PubMed ID: 27888795
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.